Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07290413 · ClinicalTrials.gov registry record · Phase 2

Photobiomodulation for the Prevention of Oral Mucositis

A Phase 2 study of Oral Mucositis, sponsored by Brigham and Women's Hospital.

Active
Registry status
Phase 2
Development phase
78
Enrollment target
1
Study location

NCT07290413 is a Phase 2 study of Oral Mucositis that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 78 participants, below the 100-participant average among 10 other Oral Mucositis trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07290413, a Phase 2 study of Oral Mucositis, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
78 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn if photobiomodulation works to prevent severe oral mucositis in patients who are undergoing allogeneic hematopoietic cell transplantation. The main questions it aims to answer are: Does 1) intraoral , 2) extraoral, or 3) combined intraoral/extraoral photobiomodulation have optimal prevention/therapeutic effect in prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT). Participants will: Be randomized to one of the three treatment arms Receive daily photobiomodulation therapy (from beginning of transplant conditioning through Day +20 after transplantation) Be evaluated for oral mucositis and symptoms daily Visit the clinic once every 2 weeks for checkups and tests Keep a diary of their symptoms and the number of times they use a rescue inhaler

Conditions Studied

Oral Mucositis

Interventions

  • DEVICE Photobiomodulation - INTRAORAL
  • DEVICE Photobiomodulation - EXTRAORAL
  • DEVICE Photobiomodulation - INTRAORAL and EXTRAORAL

Study Locations (1)

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2025-12-01
Est. Completion 2027-05
Phase Phase 2

Sponsor

Brigham and Women's Hospital

937 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07290413

The ClinicalTrials.gov registry entry for NCT07290413 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 100-participant average among 10 other Oral Mucositis trials with a reported enrollment target (22% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Oral Mucositis appearing as the primary indexed condition, and to 3 interventions - of which Photobiomodulation - INTRAORAL is the first listed.

NCT07290413 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07290413 about?

NCT07290413 is a clinical study titled "Photobiomodulation for the Prevention of Oral Mucositis". The goal of this clinical trial is to learn if photobiomodulation works to prevent severe oral mucositis in patients who are undergoing allogeneic hematopoietic cell transplantation. The main questions it aims to answer are: Does 1) intraoral , 2) extraoral, or 3) combined intraoral/extraoral photo...

What is the current status of trial NCT07290413?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2025-12-01. Estimated completion is 2027-05.

What conditions does trial NCT07290413 study?

This clinical trial studies the following conditions: Oral Mucositis.

What interventions are being tested in trial NCT07290413?

The interventions under investigation include: Photobiomodulation - INTRAORAL (DEVICE), Photobiomodulation - EXTRAORAL (DEVICE), Photobiomodulation - INTRAORAL and EXTRAORAL (DEVICE).

Who is sponsoring clinical trial NCT07290413?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07290413 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Oral Mucositis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Oral Mucositis

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.